Milliken D, Venkatesh J, Yu R, Su Z, Thompson M, Eurich D.  Comparison of drug coverage in Canada before and after the establishment of the pan-Canadian Pharmaceutical Alliance.  BMJ Open 2015;5:e008100 doi:10.1136/bmjopen-2015-008100

Lachance R, Stewart DA, Worthington K, Mistry B, Yunger S, Garnica JM, Knight S, Milliken D.  Gaps in Access to Patient Care for Patients with Rare Hematological Disorders. Blood (ASH Annual Meeting Abstracts), Nov 2011; 118: 4752

Yunger S, Ciapanna C, Shum D, Milliken D.  Clinical Efficacy and Oncology Reimbursement Recommendations in Canada by the Interim Joint Oncology Drug Review (iJODR) International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 2011

Douglas P, Yunger S, Maroun JA, Zabransky J, Byrne M, Ruzic M, Blair L, Georget G, Shum D, Milliken D.  Timeliness of private access to intravenous (IV) cancer drugs: A Canadian analysis. J Clin Oncol 28, 2010 (suppl; abstr e16533)

Blair L, Yunger S, Benn T, Sehdev SR, Shum D, Milliken D.  Canadian employers’ awareness of and willingness to include intravenous cancer medicines on employee benefit private insurance plans.  J Clin Oncol 28, 2010 (suppl; abstr e16526)

Yunger S, Ciapanna CC, Shum D, Milliken D, Longo CJ, Aissa F.  Cost- Effectiveness Observations and Oncology Drug Reimbursement Recommendations in Canada by the Joint Oncology Drug Review ISPOR, May 2010

Yunger S, Siu EC, Aissa F, Milliken D, Shum D. Understanding Drug Reimbursement Recommendations in Canada by the Common Drug Review (CDR) ISPOR, May 2010

Yunger S, Douglas P, Anglin P, Crump M, Lepage S, Shum D, Phillips L, Milliken D.  Patient Out-of-Pocket and Insurer Payment Decisions for Bevacizumab for Metastatic Colorectal Cancer: A Canadian Analysis.   J Clin Oncol (Meeting Abstracts) May 2009 vol. 27 no. 15S 6576.

Green E, Johnston M, Trudeau M, Schwartz L, Poirier S, Macartney G, Milliken D, Reynolds P.  Safe handling of parenteral cytotoxics – Recommendations for Ontario.  JOP September 2009; vol. 5 no. 5:245-249

Walker SE, Milliken D, Law S.  Stability of Bortezomib Reconstituted with 0.9% Sodium Chloride at 4C and Room Temperature (23C). CJHP 2008;61(1):14-20.

Milliken D, Sawka C, Trudeau ME.  Willingness to Pay for New Hormone-Refractory Prostate Cancer (HRPC) Therapies: Experience from Ontario Hospitals.  J Clin Oncol (Meeting Abstracts) June 2007 vol. 25 no. 18_suppl 6559

Milliken D, Cancer Care Ontario.  Presentation to 39th PARLIAMENT, 1st SESSION Standing Committee on Health (Common Drug Review), April 30, 2007.

Dranitsaris G, Evans WK, Milliken D, Zanke B.  The impact of practice guidelines and funding policies on the use of new drugs in advanced non-small cell lung cancer.  Journal of Evaluation in Clinical Practice 2005;11(4): 350.

Dranitsaris G, Johnston M, Poirier S, Schueller T, Milliken D, Green E, Zanke B. Are health care providers who work with cancer drugs at an increased risk for toxic events? A systematic review and meta-analysis of the literature.  J Oncol Pharm Pract. 2005 Jun;11(2):69-78.

Dranitsaris G, Johnston M, Poirier S, Schueller T, Savage T, Milliken D,  Green E, Evans W, Zanke B, on behalf of the Safe Handling of Cytotoxics Working Group.  Are Health Care Providers Who Work with Cancer Drugs at an Increased Risk for Toxic Events?: A Systematic Review and Meta Analysis of the Literature.    Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 6082.

Evans WK,  Dranitsaris G, Milliken D, Zanke B.  An epidemiological study using a provincial database to identify factors associated with overall survival in patients with metastatic colorectal cancer (MCC).    Proc Am Soc Clin Oncol 22: 2003 (abstr 1505)

Pearson G, Milliken D, Pao D, Rosenbloom D, Loo C.  Prescribing by Pharmacists in Canadian Hospitals, CSHP, Professional Practice Conference (Poster), 1997.

Milliken D, Friesen E.  Program Management and Beyond –  The Perspective from two Hospitals.  Hosp Pharm Practice 1997;5(2):18-27.

Milliken D.  Implementation of an Aminoglycoside Dosing Service – An Example of Pharmacist-Directed Drug Therapy., CSHP, Professional Practice Conference (Poster), 1992.

Milliken DL, Gervais AA, Wilson KB.  Impact of Computerization on Medication Discrepancies in a Centralized Unit Dose Drug Distribution System.  Hosp Pharm 1990;25:650-652.